
Claims


1. Use of a compound of formula (I),



formula (I)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment, prevention, or alleviation of female sexual dysfunction in a subject.

2. The use according to claim 1, wherein the compound has the structure of formula (Ia);



formula (Ia),

or a pharmaceutically acceptable salt thereof.

3. The use according to claim 2, wherein the compound is exo-7-[(8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one or a pharmaceutically acceptable salt thereof.

4. The use according to any one of the preceding claims wherein the compound is exo-7-[(8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one hydrochloride.

5. The use according to any one of the preceding claims, wherein the female sexual dysfunction is selected from the group consisting of:
   (i) female sexual interest/arousal disorder,
   (ii) hypoactive sexual desire dysfunction,
   (iii) female sexual arousal dysfunction
   (iv) orgasmic dysfunction,
   (v) sexual pain disorder, and
   (vi) dyspareunia.

6. The use according to any one of the preceding claims, wherein the female sexual dysfunction is female sexual interest/arousal disorder (FSIAD).

7. The use according to any one of the preceding claims, wherein the female sexual dysfunction is female sexual arousal dysfunction.

8. The use according to any one of the preceding claims, wherein the orgasmic dysfunction is anorgasmia.

9. The use according to any one of the preceding claims, wherein the female sexual dysfunction is sexual pain disorder.

10. The use according to any one of the preceding claims, wherein the sexual pain disorder is vulvodynia, or progressive vulvodynia.

11. The use according to any one of the preceding claims, wherein the female sexual dysfunction is a hypoactive female sexual desire dysfunction.

12. The use according to any one of the preceding claims, wherein the female sexual disorder is not a hyperactive female sexual disorder, such as premature female orgasm.

13. The use according to any one of the preceding claims, wherein the subject prior to treatment had a female sexual function index (FSFI) of less than 26.55, such as 25.00 to 26.55, such as 20.00 to 25.00, such as 15.00 to 20.00, such as 10.00 to 15.00, such as 5.00 to 10.00, such as 2.00 to 5.00.

14. The use according to any one of the preceding claims, wherein the compound is capable of increasing the FSFI, the FSFI-6, and/or the EDQ and/or decreasing the FSDS-DAO in the subject.

15. The use according to any one of the preceding claims, wherein the compound is capable of increasing the FSFI score of any one or more of the domains: desire, arousal, lubrication, orgasm, and satisfaction.

16. The use according to any one of the preceding claims, wherein the subject is a human female.

17. The use according to any one of the preceding claims, wherein the subject is fertile, pre-menopausal, menopausal, or post-menopausal.

18. The use according to any one of the preceding claims wherein the subject is over the age of 18, such as over the age of 20, such as over the age of 25, such as over the age of 30, such as over the age of 35, such as over the age of 40, such as over the age of 45, such as over the age of 50, such as over the age of 55, such as over the age of 60, such as over the age of 65, such as over the age of 70, such as over the age of 75.

19. The use according to any one of the preceding claims, wherein the treatment, prevention, or alleviation of female sexual dysfunction results in :

(i) increasing the vaginal temperature in the subject,

(ii) increasing the genital blood flow in the subject,


(iii) increasing the genital temperature in the subject, such as the genital temperature in the clitoris, vagina, labia, or any combination thereof;

(iv) increasing sexual desire, sexual interest, sexual arousal, lubrication, sexual satisfaction, or a combination thereof in the subject;

(v) reducing sexual pain in the subject; and/or

(vi) reducing difficulty in reaching orgasm upon sexual stimulation or intercourse in a subject.

20. Use of a compound of formula (I),



formula (I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing sexual pain in a subject.